EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design and Synthesis of Pyrimidino[4,5‐ d ]Pyrimidine‐Based Compounds as Potent B‐RAF V600E Inhibitors

Eleftheria A Georgiou, Kalliopi Christopoulou, Amalia D Kalampaliki, Aikaterini F Giannopoulou, Eleftheria Chatziorfanou, Vivi Bafiti, Andreas Krämer, Athanasios Papakyriakou, Dimitrios J Stravopodis, Stefan Knapp, Ioannis K Kostakis iD

ChemMedChem · 15.06.2026 · 21 (11)

DOI: 10.1002/cmdc.70324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 28.05.2026. Verfasst von Eleftheria A Georgiou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Pyrimidines, Protein Kinase Inhibitors, Drug Design. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitogen‐activated protein kinase (MAPK) pathway plays a central role in regulating cellular proliferation, differentiation, and survival, and its aberrant activation is a hallmark of numerous cancers. B‐RAF, a key kinase in this pathway, is frequently mutated, with the B‐RAF V600E variant being highly prevalent in melanoma. Here, we report the design, synthesis, and biological evaluation of novel pyrimido[4,5‐ d ]pyrimidine‐based compounds targeting B‐RAF. The compounds were rationally designed to incorporate key pharmacophoric features of known B‐RAF inhibitors to enhance selectivity and potency against B‐RAF. Kinase profiling using differential scanning fluorimetry (DSF) and isothermal titration calorimetry (ITC) showed that compound 15 binds selectively to B‐RAF V600E ( K d = 98 nM) with minimal off‐target interactions. Docking studies supported a type‐II binding mode in a DFG‐out/αC‐helix‐in conformation, highlighting key hydrogen‐bonding and hydrophobic interactions within the ATP‐binding cleft. Despite its strong biochemical profile, 15 showed only modest antiproliferative activity in T24 and WM266−4 cancer cells, suggesting limitations related to cellular permeability or efflux. In contrast, compounds 16 , 17 , and 22 displayed marked cellular activity despite limited B‐RAF inhibition, indicating potential contributions from alternative kinases or yet unidentified off‐target mechanisms. The large DSF Tm shifts observed established the poorly exploited pyrimido[4,5‐ d ]pyrimidines as interesting ATP mimetic scaffolds for kinase inhibitor development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafPyrimidinesProtein Kinase InhibitorsDrug DesignAntineoplastic AgentsHumansCell ProliferationStructure-Activity RelationshipCell Line, TumorMolecular Docking SimulationMolecular StructureDose-Response Relationship, DrugDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

B‐RAF V600Emelanomapyrimido[4,5‐d]pyrimidine

Substanzen

Proto-Oncogene Proteins B-rafPyrimidinesProtein Kinase InhibitorsAntineoplastic AgentsBRAF protein, human

Autor:innen und Institutionen

  • Division of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
  • Section of Cell Biology and Biophysics, Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
  • Institute for Pharmaceutical Chemistry, Department of Biochemistry, Chemistry and Pharmacy, Goethe University Frankfurt, Frankfurt, Germany.
  • Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt, Germany.
  • Institute of Biosciences and Applications, National Centre for Scientific Research "Demokritos", Athens, Greece.

ORCID-Profile: Ioannis K Kostakis

Zitieren

APA

Georgiou, E. A., Christopoulou, K., Kalampaliki, A. D., Giannopoulou, A. F., Chatziorfanou, E., Bafiti, V., Krämer, A., Papakyriakou, A., Stravopodis, D. J., Knapp, S., & Kostakis, I. K. (2026). Design and Synthesis of Pyrimidino[4,5‐ d ]Pyrimidine‐Based Compounds as Potent B‐RAF V600E Inhibitors. ChemMedChem, 21(11). https://doi.org/10.1002/cmdc.70324

Vancouver

Georgiou EA, Christopoulou K, Kalampaliki AD, Giannopoulou AF, Chatziorfanou E, Bafiti V, et al. Design and Synthesis of Pyrimidino[4,5‐ d ]Pyrimidine‐Based Compounds as Potent B‐RAF V600E Inhibitors. ChemMedChem. 2026;21(11). doi:10.1002/cmdc.70324

BibTeX
@article{Georgiou2026,
  author = {Georgiou, Eleftheria A and Christopoulou, Kalliopi and Kalampaliki, Amalia D and Giannopoulou, Aikaterini F and Chatziorfanou, Eleftheria and Bafiti, Vivi and Krämer, Andreas and Papakyriakou, Athanasios and Stravopodis, Dimitrios J and Knapp, Stefan and Kostakis, Ioannis K},
  title = {Design and Synthesis of Pyrimidino[4,5‐ d ]Pyrimidine‐Based Compounds as Potent B‐RAF V600E Inhibitors},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {11},
  doi = {10.1002/cmdc.70324}
}
Kostenlos starten →